Business Context and Reporting Period
Oaktree Acquisition Corp. III Life Sciences is a Cayman Islands exempted company formed as a blank check entity to effect a business combination with one or more life sciences businesses. The company is an emerging growth company and a shell company. As of the filing date, no specific business combination target has been selected. The reporting period covers the quarter and nine months ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | Balance Sheet (Sep 30, 2025) |
|---|---|---|---|
| Net Income (Loss) | $1,966,742 | $5,499,876 | — |
| Operating Expenses | $(225,579) | $(940,191) | — |
| Interest Income (Trust Account) | $2,192,321 | $6,440,067 | — |
| Cash (Outside Trust) | — | — | $1,328,841 |
| Cash in Trust Account | — | — | $199,769,089 |
| Total Assets | — | — | $201,249,963 |
| Total Liabilities | — | — | $8,245,536 |
| Working Capital | — | — | $254,086 |
| Deferred Underwriting Fees | — | — | $6,719,660 |
Material Changes vs. Prior Period
- Profitability Shift: The company transitioned from a net loss of $48,095 for the three months ended September 30, 2024, to a net income of $1,966,742 for the same period in 2025. This is primarily driven by interest income earned on the Trust Account, which was non-existent in the prior period as the IPO had not yet closed.
- Trust Account Growth: Cash held in the Trust Account increased from $193,579,022 at December 31, 2024, to $199,769,089 at September 30, 2025, reflecting accumulated interest income.
- Expense Increase: General and administrative expenses increased to $225,579 for Q3 2025 compared to $48,095 in Q3 2024, reflecting ongoing operational costs post-IPO.
- Related Party Liabilities: A new liability of $710,857 "Due to related party" appeared in Q3 2025, compared to zero in the prior year-end, alongside a promissory note of $11,824.
Outlook, Risks, and Management Commentary
- Business Combination Deadline: The company must complete an initial business combination by October 25, 2026 (24 months from the IPO closing). Failure to do so will result in mandatory liquidation and dissolution.
- Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. While the company has $1.33 million in cash outside the trust, it expects to incur significant costs and may need to raise additional capital through loans or investments from the Sponsor or third parties. There is no assurance such financing will be available.
- Redemption Rights: Public shareholders have the right to redeem their shares for a pro rata portion of the Trust Account (approximately $10.41 per share as of September 30, 2025) upon the completion of a business combination or liquidation.
- Management Changes: In a subsequent event, Thomas Sweeney resigned as Chief Financial Officer on October 29, 2025, and was replaced by George A. Martinez. Additionally, David A. Berry, MD, PhD, was appointed as an independent director.
- Risk Factors: Risks include the inability to complete a business combination, market volatility, geopolitical conflicts (Ukraine/Russia, Israel/Hamas), and the potential for the Sponsor to be unable to satisfy indemnification obligations if third-party claims reduce Trust Account funds.
Investor Verification Checklist
- Trust Account Balance: Verify the current per-share redemption value ($10.41 as of Sep 30, 2025) and confirm interest accrual rates.
- Extension Possibility: Assess the likelihood of the company seeking a shareholder vote to extend the combination period beyond October 2026, which would likely trigger redemptions.
- Related Party Exposure: Review the $710,857 "Due to related party" and the $25,000 monthly administrative fee agreement to understand ongoing cash burn outside the trust.
- Deferred Fees: Note the $6.72 million deferred underwriting fee payable only upon a successful business combination.
- Capital Needs: Monitor disclosures regarding the need for additional working capital loans from the Sponsor to fund operations until the deadline.